{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:51:23Z","timestamp":1790704283433,"version":"4.1.0"},"reference-count":54,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T00:00:00Z","timestamp":1568505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Vanderbilt Clinical and Translational Science Awards","award":["UL1 TR000445-06"],"award-info":[{"award-number":["UL1 TR000445-06"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK059637"],"award-info":[{"award-number":["DK059637"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK020593"],"award-info":[{"award-number":["DK020593"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K23HL11962"],"award-info":[{"award-number":["K23HL11962"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL125426"],"award-info":[{"award-number":["R01HL125426"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Women with polycystic ovarian syndrome (PCOS) have decreased growth hormone (GH), which can result in increased visceral adiposity (VAT) and impaired vascular function. GH-releasing hormone, a dipeptidyl peptidase-4 (DPP4) substrate, stimulates GH secretion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We tested the hypothesis that DPP4 inhibition increases GH and improves glucose levels and vascular function in women with PCOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eighteen women with PCOS participated in a double-blind, crossover study. They received sitagliptin either 100 mg or placebo daily for 1 month, with crossover treatments separated by an 8-week washout. During each treatment, women underwent a 75-gram oral glucose tolerance test (OGTT) and assessments of vascular function and body composition. Overnight GH secretion was assessed via venous sampling every 10 minutes for 12 hours and analyzed using an automated deconvolution algorithm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During OGTT, sitagliptin increased glucagon-like peptide-1 (P &amp;lt; 0.001), early insulin secretion (from mean [\u00b1 SD] insulinogenic index 1.9 \u00b1 1.2 to 3.2 \u00b1 3.1; P = 0.02), and decreased peak glucose (mean \u221217.2 mg\/dL [95% CI, \u221227.7 to \u22126.6]; P &amp;lt; 0.01). At 1 month, sitagliptin decreased VAT (from 1141.9 \u00b1 700.7 to 1055.1 \u00b1 710.1 g; P = 0.02) but did not affect vascular function. Sitagliptin increased GH half-life (from 13.9 \u00b1 3.6 to 17.0 \u00b1 6.8 min, N = 16; P = 0.04) and interpulse interval (from 53.2 \u00b1 20.0 to 77.3 \u00b1 38.2 min, N = 16; P &amp;lt; 0.05) but did not increase mean overnight GH (P = 0.92 vs placebo).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sitagliptin decreased the maximal glucose response to OGTT and VAT. Sitagliptin did not increase overnight GH but increased GH half-life and the interpulse interval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>This study was registered at www.clinicaltrials.gov as NCT02122380 prior to enrollment of the first participant.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgz028","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T15:49:42Z","timestamp":1568735382000},"page":"136-151","source":"Crossref","is-referenced-by-count":35,"title":["Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9866-4635","authenticated-orcid":false,"given":"Jessica K","family":"Devin","sequence":"first","affiliation":[{"name":"Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Nian","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E","family":"Celedonio","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Wright","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J","family":"Brown","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,9,15]]},"reference":[{"key":"2021122117114434900_CIT0001","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1210\/jc.2007-2021","article-title":"Growth hormone exerts acute vascular effects independent of systemic or muscle insulin-like growth factor I","volume":"93","author":"Li","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122117114434900_CIT0002","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1210\/jc.2003-030144","article-title":"Acute effects of growth hormone on vascular function in human subjects","volume":"88","author":"Napoli","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122117114434900_CIT0003","doi-asserted-by":"crossref","first-page":"111","DOI":"10.7326\/0003-4819-133-2-200007180-00010","article-title":"Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial","volume":"133","author":"Sesmilo","year":"2000","journal-title":"Ann Intern Med"},{"key":"2021122117114434900_CIT0004","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1210\/jc.2007-0609","article-title":"Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency","volume":"92","author":"Devin","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122117114434900_CIT0005","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ghir.2013.08.005","article-title":"Growth hormone replacement normalizes impaired fibrinolysis: new insights into endothelial dysfunction in patients with hypopituitarism and growth hormone deficiency","volume":"23","author":"Miljic","journal-title":"Growth Horm IGF Res"},{"key":"2021122117114434900_CIT0006","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1210\/jcem.86.11.8061","article-title":"Altered neuroregulation of GH secretion in viscerally obese premenopausal women","volume":"86","author":"Pijl","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122117114434900_CIT0007","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ecl.2006.11.005","article-title":"Effects of growth hormone on glucose and fat metabolism in human subjects","volume":"36","author":"Jorgensen","year":"2007","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2021122117114434900_CIT0008","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1172\/JCI114049","article-title":"Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma","volume":"83","author":"Frohman","year":"1989","journal-title":"J Clin Invest"},{"key":"2021122117114434900_CIT0009","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1172\/JCI112679","article-title":"Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus","volume":"78","author":"Frohman","year":"1986","journal-title":"J Clin Invest"},{"key":"2021122117114434900_CIT0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clinthera.2006.01.015","article-title":"Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers","volume":"28","author":"Bergman","year":"2006","journal-title":"Clin Ther"},{"key":"2021122117114434900_CIT0011","article-title":"Dipeptidyl Peptidase-4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women","volume":"2018;7:e008000","author":"Wilson","journal-title":"J Am Heart Assoc"},{"key":"2021122117114434900_CIT0012","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/humrep\/deh122","article-title":"Growth hormone secretion is impaired but not related to insulin sensitivity in non-obese patients with polycystic ovary syndrome","volume":"19","author":"de Boer","year":"2004","journal-title":"Hum Reprod"},{"key":"2021122117114434900_CIT0013","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF03345138","article-title":"GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome","volume":"26","author":"Orio","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"2021122117114434900_CIT0014","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2265.1995.tb02691.x","article-title":"Dysfunction of the growth hormone\/insulin-like growth factor-I axis in women with polycystic ovarian syndrome","volume":"42","author":"Piaditis","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021122117114434900_CIT0015","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1210\/jc.2005-0628","article-title":"Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span","volume":"90","author":"Azziz","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122117114434900_CIT0016","first-page":"183","year":"2004"},{"key":"2021122117114434900_CIT0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CLEP.S37559","article-title":"Epidemiology, diagnosis, and management of polycystic ovary syndrome","volume":"6","author":"Sirmans","year":"2013","journal-title":"Clin Epidemiol"},{"key":"2021122117114434900_CIT0018","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome","volume":"81","year":"2004","journal-title":"Fertil Steril"},{"key":"2021122117114434900_CIT0019","first-page":"1976","article-title":"Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS)","volume":"83","author":"Cronin","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122117114434900_CIT0020","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jclinepi.2003.10.018","article-title":"Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated","volume":"57","author":"Guyatt","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"2021122117114434900_CIT0021","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/humrep\/deh048","article-title":"The polycystic ovary syndrome health-related quality of life questionnaire (PCOSQ): a validation","volume":"19","author":"Jones","year":"2004","journal-title":"Hum Reprod"},{"key":"2021122117114434900_CIT0022","article-title":"Time-course analysis of flow mediated dilation` for the evaluation of endothelial function after a high-fat meal in African Americans","volume":"2015;4:e002388","author":"Marinos","journal-title":"J Am Heart Assoc"},{"key":"2021122117114434900_CIT0023","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1161\/HYPERTENSIONAHA.107.101014","article-title":"Importance of measuring the time course of flow-mediated dilatation in humans","volume":"51","author":"Black","year":"2008","journal-title":"Hypertension"},{"key":"2021122117114434900_CIT0024","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1161\/hy0202.103054","article-title":"Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema","volume":"39","author":"Lefebvre","year":"2002","journal-title":"Hypertension"},{"key":"2021122117114434900_CIT0025","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.freeradbiomed.2012.09.030","article-title":"Measurement of F2- isoprostanes and isofurans using gas chromatography-mass spectrometry","volume":"59","author":"Milne","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"2021122117114434900_CIT0026","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4239\/wjd.v1.i2.36","article-title":"Surrogate markers of insulin resistance: A review","volume":"1","author":"Singh","year":"2010","journal-title":"World J Diabetes"},{"key":"2021122117114434900_CIT0027","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"key":"2021122117114434900_CIT0028","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ab.2008.07.001","article-title":"AutoDecon, a deconvolution algorithm for identification and characterization of luteinizing hormone secretory bursts: description and validation using synthetic data","volume":"381","author":"Johnson","year":"2008","journal-title":"Anal Biochem"},{"key":"2021122117114434900_CIT0029","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0076-6879(08)03815-9","article-title":"AutoDecon: a robust numerical method for the quantification of pulsatile events","volume":"454","author":"Johnson","year":"2009","journal-title":"Methods Enzymol"},{"key":"2021122117114434900_CIT0030","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-0-12-381272-8.00014-3","article-title":"Model-based evaluation of growth hormone secretion","volume":"514","author":"Veldhuis","journal-title":"Methods Enzymol"},{"key":"2021122117114434900_CIT0031","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1210\/jc.2010-1587","article-title":"Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men","volume":"96","author":"Stanley","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122117114434900_CIT0032","volume-title":"Design and Analysis of Crossover Trials","author":"Jones B"},{"key":"2021122117114434900_CIT0033","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0197-2456(90)90005-M","article-title":"Power and sample size calculations. A review and computer program","volume":"11","author":"Dupont","year":"1990","journal-title":"Control Clin Trials."},{"key":"2021122117114434900_CIT0034","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1530\/EJE-08-0097","article-title":"Incretin levels in polycystic ovary syndrome","volume":"159","author":"Vrbikova","year":"2008","journal-title":"Eur J Endocrinol."},{"key":"2021122117114434900_CIT0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.metabol.2017.03.008","article-title":"Exaggerated glucagon responses to hypoglycemia in women with polycystic ovary syndrome","volume":"71","author":"Sam","journal-title":"Metabolism"},{"key":"2021122117114434900_CIT0036","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4158\/EP-2017-0027","article-title":"Dpp4 Inhibitor sitagliptin as a potential treatment option in metformin-intolerant obese women with polycystic ovary syndrome: a pilot randomized study","volume":"24","author":"Ferjan","year":"2018","journal-title":"Endocr Pract"},{"key":"2021122117114434900_CIT0037","first-page":"2261","article-title":"In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion","volume":"82","author":"Grottoli","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122117114434900_CIT0038","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1210\/jc.2011-3317","article-title":"Distinct metabolic surrogates predict basal and rebound GH secretion after glucose ingestion in men","volume":"97","author":"Iranmanesh","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122117114434900_CIT0039","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ghir.2014.01.003","article-title":"GLP-1 infusion reduces IGFBP-1 serum level in humans","volume":"24","author":"Skov","year":"2014","journal-title":"Growth Horm IGF Res"},{"key":"2021122117114434900_CIT0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1210\/jcem-72-1-51","article-title":"Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man","volume":"72","author":"Veldhuis","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122117114434900_CIT0041","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1210\/jc.2012-2794","article-title":"Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial","volume":"97","author":"Makimura","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122117114434900_CIT0042","first-page":"E1108","article-title":"Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults","volume":"272","author":"Vahl","year":"1997","journal-title":"Am J Physiol"},{"key":"2021122117114434900_CIT0043","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ghir.2018.03.003","article-title":"The effect of growth hormone on bioactive IGF in overweight\/obese women","volume":"40","author":"Dichtel","year":"2018","journal-title":"Growth Horm IGF Res"},{"key":"2021122117114434900_CIT0044","first-page":"123","article-title":"Abdominal fat determines growth hormone-binding protein levels in healthy nonobese adults","volume":"82","author":"Fisker","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122117114434900_CIT0045","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1161\/HYPERTENSIONAHA.113.02767","article-title":"Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition","volume":"63","author":"Devin","year":"2014","journal-title":"Hypertension"},{"key":"2021122117114434900_CIT0046","doi-asserted-by":"crossref","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD","author":"Yan","year":"2019;69:2414\u20132426","journal-title":"Hepatology"},{"key":"2021122117114434900_CIT0047","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1089\/met.2017.0095","article-title":"Dipeptidyl peptidase-4 inhibitor sitagliptin prevented weight regain in obese women with polycystic ovary syndrome previously treated with liraglutide: a pilot randomized study","volume":"15","author":"Ferjan","year":"2017","journal-title":"Metab Syndr Relat Disord"},{"key":"2021122117114434900_CIT0048","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1210\/jc.2007-0922","article-title":"Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-I","volume":"92","author":"Thum","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122117114434900_CIT0049","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1677\/joe.1.05726","article-title":"Growth hormone-induced blood pressure decrease is associated with increased mRNA levels of the vascular smooth muscle KATP channel","volume":"183","author":"Tivesten","year":"2004","journal-title":"J Endocrinol"},{"key":"2021122117114434900_CIT0050","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/HYPERTENSIONAHA.118.11498","article-title":"DPP (Dipeptidyl Peptidase)-4 inhibition potentiates the vasoconstrictor response to NPY (Neuropeptide Y) in humans during renin-angiotensin-aldosterone system inhibition","volume":"72","author":"Hubers","journal-title":"Hypertension"},{"key":"2021122117114434900_CIT0051","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001075","article-title":"Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm","volume":"3","author":"Devin","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2021122117114434900_CIT0052","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.amjcard.2014.11.044","article-title":"Effect of dipeptidyl peptidase-4 inhibitor, vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus","volume":"115","author":"Tani","year":"2015","journal-title":"Am J Cardiol"},{"key":"2021122117114434900_CIT0053","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1210\/jc.2012-1544","article-title":"Sitagliptin exerts an antinflammatory action","volume":"97","author":"Makdissi","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122117114434900_CIT0054","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1210\/js.2017-00312","article-title":"Hypertension and type 2 diabetes are associated with decreased inhibition of dipeptidyl peptidase-4 by sitagliptin","volume":"1","author":"Wilson","year":"2017","journal-title":"J Endocr Soc"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgz028\/30022850\/dgz028.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/1\/136\/41841798\/dgz028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/1\/136\/41841798\/dgz028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T12:24:20Z","timestamp":1640089460000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/1\/136\/5569914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,15]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,9,15]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgz028","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/19001685","asserted-by":"object"}]},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2019,9,15]]}}}